Previous 10 | Next 10 |
Stealth BioTherapeutics CEO to Give Keynote Presentation at Mitochondria-Targeted Drug Development Summit PR Newswire BOSTON , April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discov...
Shares of Stealth BioTherapeutics Corp. (NASDAQ:MITO) traded today at $1.10, breaking its 52-week low. So far today approximately 850,000 shares have been exchanged, as compared to an average 30-day volume of 231,000 shares. In the past 52 weeks, Stealth BioTherapeutics Corp. share price...
Stealth BioTherapeutics Corp. (NASDAQ:MITO) traded at a new 52-week low today of $1.08. Approximately 850,000 shares have changed hands today, as compared to an average 30-day volume of 231,000 shares. There is potential upside of 22.2% for shares of Stealth BioTherapeutics Corp. based o...
Stealth BioTherapeutics Corp. (NASDAQ:MITO) traded today at a new 52-week low of $1.15. This new low was reached on above average trading volume as 850,000 shares traded hands, while the average 30-day volume is approximately 231,000 shares. In the past 52 weeks, Stealth BioTherapeutics ...
Provention Bio (PRVB) -38% after gives update on teplizumab BLA, FDA feedback.Virpax Pharmaceuticals (VRPX) -18%.Chemomab Therapeutics (CMMB) -17%.Iterum Therapeutics (ITRM) -15% after receiving notice from FDA on its NDA drug application for sulopenem etzadroxil/probenecid for...
Stealth BioTherapeutics (MITO) shares fell more than 10% yesterday after the company reported no revenue for 2020 and indicated it may have to delay an NDA filing for elamipretide for cardiomyopathy in Barth syndrome.The company's 2020 EPS also missed analyst expectations.Regarding ...
Stealth BioTherapeutics Corp (MITO) Q4 2020 Results Earnings Conference Call April 06, 2021, 08:30 AM ET Company Participants Henry Hess - Chief Legal Counsel Reenie McCarthy - Chief Executive Officer Jim Carr - Chief Clinical Development Officer Rob Weiskopf - Chief Financial Officer Brian B...
Gainers: Brooklyn ImmunoTherapeutics (BTX) +45%, Greenwich LifeSciences (GLSI) +16%, PAVmed (PAVM) +15%, SeaSpine Holdings (SPNE) +14%, Cara Therapeutics (CARA) +14%.Losers: Scholar Rock (SRRK) -14%, Chembio Diagnostics (CEMI) -13%, Harmo...
Stealth BioTherapeutics (MITO): FY GAAP EPS of -$0.10 misses by $0.08.Cash and cash equivalents of $32.8MShares are up 7.8% PM.Press Release For further details see: Stealth BioTherapeutics EPS misses by $0.08
Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on re...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...